IL17A and psoriasis: In a clinical trial, endothelial function—measured by flow-mediated dilation (FMD)—exhibited improvement in patients with psoriasis following treatment with inhibitors targeting tumor necrosis factor-alpha (TNF-α) and Interleukin (IL)-17A [29,30].